Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Ohmi, Yuhsuke ^a,b   Ise, Wataru ^c   Harazono, Akira ^d   Takakura, Daisuke ^e   Fukuyama, Hidehiro ^f   Baba, Yoshihiro ^c   Narazaki, Masashi ^g   Shoda, Hirofumi ^h   Takahashi, Nobunori ^a   Ohkawa, Yuki ^a,i   Ji, Shuting ^a   Sugiyama, Fumihiro ^j   Fujio, Keishi ^h   Kumanogoh, Atsushi ^g   Yamamoto, Kazuhiko ^h   Kawasaki, Nana ^d,e   Kurosaki, Tomohiro ^c,f   Takahashi, Yoshimasa ^b   Furukawa, Koichi ^a,i  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

^f RIKEN Center for Integrative Medical Sciences   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ CHUBU UNIVERSITY   (Japan)

^j UNIVERSITY OF TSUKUBA   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI CITRULLINATED PROTEIN ANTIBODY; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOGLOBULIN G; SIALIC ACID DERIVATIVE;

ANTIBODY; ANTIGEN; CELLS AND CELL COMPONENTS; COLLAGEN; DISEASE CONTROL; ECOLOGICAL MODELING; IMMUNE SYSTEM; INHIBITOR; MONOSACCHARIDE; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTHRITOGENIC ACTIVITY; ARTICLE; B LYMPHOCYTE; COLLAGEN ANTIBODY-INDUCED ARTHRITIS; CONTROLLED STUDY; DISEASE EXACERBATION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; LIQUID CHROMATOGRAPHY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIALYLATION; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CARBOHYDRATE ANALYSIS; CHEMISTRY; DBA MOUSE; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS; TRANSGENIC MOUSE;

MUS;

AMINO ACID SEQUENCE; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CARBOHYDRATE SEQUENCE; COLLAGEN TYPE II; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIALIC ACIDS;

EID: 84964054247     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11205     Document Type: Article

References (55)

1. Shahouri S. H, et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum. 63, 3204-3215 (2011).
2. Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580-1588 (2010).
3. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, & Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26, 651-675 (2008).
4. Nielen M. M, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380-386 (2004).
5. Snir O, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 62, 44-52 (2010).
6. Kleyer A, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann. Rheum. Dis. 73, 854-860 (2014).
7. Laurent L, et al. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann. Rheum. Dis. 74, 1425-1431 (2015).
8. Harre U, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791-1802 (2012).
9. Harre U, et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat. Commun. 6, 6651 (2015).
10. Kuhn K. A, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 116, 961-973 (2006).
11. Uysal H, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 206, 449-462 (2009).
12. Arnold J. N, Wormald M. R, Sim R. B, Rudd P. M, & Dwek R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007).
13. Parekh R. B, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 316, 452-457 (1985).
14. Rook G. A, et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J. Autoimmun. 4, 779-794 (1991).
15. Malhotra R, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1, 237-243 (1995).
16. Scherer H. U, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 62, 1620-1629 (2010).
17. Rademacher T. W, Williams P, & Dwek R. A. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc. Natl Acad. Sci. USA. 91, 6123-6127 (1994).
18. Ito K, et al. Lack of galactosylation enhances the pathogenic activity of IgG1 but Not IgG2a anti-erythrocyte autoantibodies. J. Immunol. 192, 581-588 (2014).
19. Karsten C. M, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat. Med. 18, 1401-1406 (2012).
20. Oefner C. M, et al. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J. Allergy Clin. Immunol. 129, 1647-1655 e1613 (2012).
21. Hess C, et al. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J. Clin. Invest. 123, 3788-3796 (2013).
22. Anthony R. M, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 320, 373-376 (2008).
23. von Gunten S, et al. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat. Rev. Immunol. 14, 349 (2014).
24. Leontyev D, et al. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion. 52, 1799-1805 (2012).
25. Bond A, Cooke A, & Hay F. C. Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis. Eur. J. Immunol. 20, 2229-2233 (1990).
26. Mizuochi T, Hamako J, Nose M, & Titani K. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J. Immunol. 145, 1794-1798 (1990).
27. Willemze A, et al. The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. Ann. Rheum. Dis. 72, 1059-1063 (2013).
28. Vossenaar E. R, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum. 48, 2489-2500 (2003).
29. Holmdahl R, Rubin K, Klareskog L, Larsson E, & Wigzell H. Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-Type II collagen antibodies. Arthritis Rheum. 29, 400-410 (1986).
30. Nordling C, Holmdahl R, & Klareskog L. Down-regulation of collagen arthritis after in vivo treatment with a syngeneic monoclonal anti-idiotypic antibody to a cross-reactive idiotope on collagen II auto-Antibodies. Immunology. 72, 486-490 (1991).
31. Nandakumar K. S, Svensson L, & Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice. Am. J. Pathol. 163, 1827-1837 (2003).
32. Ito K, et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183, 2635-2644 (1996).
33. Hill J. A, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J. Exp. Med. 205, 967-979 (2008).
34. Kaneko Y, Nimmerjahn F, & Ravetch J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 313, 670-673 (2006).
35. Crouch E. E, et al. Regulation of AID expression in the immune response. J. Exp. Med. 204, 1145-1156 (2007).
36. Shibuya N, et al. The elderberry (Sambucus nigra L) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J. Biol. Chem. 262, 1596-1601 (1987).
37. Shibuya N, et al. Fractionation of sialylated oligosaccharides, glycopeptides, and glycoproteins on immobilized elderberry (Sambucus nigra L) bark lectin. Arch. Biochem. Biophys. 254, 1-8 (1987).
38. Schwab I, Biburger M, Kronke G, Schett G, & Nimmerjahn F. IVIgmediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 42, 826-830 (2012).
39. Schwab I, et al. Broad requirement for terminal sialic acid residues and FcgammaRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur. J. Immunol. 44, 1444-1453 (2014).
40. Suwannalai P, et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 64, 1323-1328 (2012).
41. Sokolove J, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 7, e35296 (2012).
42. Rombouts Y, et al. Anti-citrullinated protein antibodies acquire a proinflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann. Rheum. Dis. 74, 234-241 (2015).
43. Nimmerjahn F, Anthony R. M, & Ravetch J. V. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl Acad. Sci. USA. 104, 8433-8437 (2007).
44. Anthony R. M, Wermeling F, Karlsson M. C, & Ravetch J. V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl Acad. Sci. USA. 105, 19571-19578 (2008).
45. Schwab I, & Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176-189 (2013).
46. Anthony R. M, Kobayashi T, Wermeling F, & Ravetch J. V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 475, 110-113 (2011).
47. Washburn N, et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc. Natl Acad. Sci. USA. 112, E4339 (2015).
48. Holmdahl R, Jansson L, Larsson E, Rubin K, & Klareskog L. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum. 29, 106-113 (1986).
49. Tuncel J, et al. Class II major histocompatibility complex-Associated response to type XI collagen regulates the development of chronic arthritis in rats. Arthritis Rheum. 64, 2537-2547 (2012).
50. Narimatsu H, Sinha S, Brew K, Okayama H, & Qasba P. Cloning and sequencing of cDNA of bovine N-Acetylglucosamine (beta 1-4)galactosyltransferase. Proc. Natl Acad. Sci. USA. 83, 4720-4724 (1986).
51. Berger E. G, Thurnher M, & Müller U. Galactosyltransferase and sialyltransferase are located in different subcellular compartments in HeLa cells. Exp. Cell Res. 173, 267-273 (1987).
52. Shur B. D, & Roth S. Cell surface glycosyltransferases. Biochim. Biophys. Acta. 415, 473-512 (1975).
53. Schachter M, & Rodén L. In Metabolic Conjugation and Metabolic HydrolysisFishman W. H. (ed (Academic Press3, 1-149, 1973).
54. Axford J. S, et al. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J. Clin. Invest. 89, 1021-1031 (1992).
55. Shimaoka H, et al. One-pot solid-phase glycoblotting and probing by transoximization for high-Throughput glycomics and glycoproteomics. Chemistry. 13, 1664-1673 (2007).